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Abstract: For more than 20 years, tamoxifen has been the gold standard for the adjuvant 
treatment of postmenopausal women with hormone-responsive early breast cancer. However, 
recent randomized trials have shown efﬁ  cacy and tolerability beneﬁ  ts with the third-generation 
aromatase inhibitor anastrozole, resulting in an increased use of this agent in the adjuvant 
setting. Data on anastrozole’s long-term efﬁ  cacy and tolerability are therefore of interest in 
clinical practice and will be reviewed here, especially in the light of the 100-month analysis of 
the ATAC (Anastrozole, Tamoxifen Alone or in Combination) trial.
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Introduction
Breast cancer is the single most commonly diagnosed cancer in women worldwide and 
a leading cause of cancer-related death. In Western countries, nearly 75% of all breast 
cancers occur in postmenopausal women, of which about 80% are hormone-receptor 
positive. A recent retrospective analysis of 3614 postmenopausal patients with estrogen 
receptor-positive (ER+) early breast cancer treated with adjuvant tamoxifen revealed 
that 476 (13.2%) had developed a recurrence during the 5-year median follow-up.1 
The annual hazard ratio (HR) of recurrence peaked at 2 years (4.3% per annum); the 
majority of this peak represented distant recurrence. In another retrospective cohort 
study of US patients (n = 1616) with early breast cancer, the risk of dying was found 
to be over 3 times greater for patients with distant recurrence as compared with loco-
regional or contralateral recurrence.2
Given the potential adverse impact on overall survival associated with recurrence, 
adjuvant therapies that reduce the risk of early distant metastasis are also most likely 
to have a signiﬁ  cant beneﬁ  cial effect on overall survival. Tamoxifen has been for a 
long time the adjuvant treatment of choice for pre- and postmenopausal women with 
hormone receptor positive early breast cancer. The results of the Oxford meta-analyses3,4 
have demonstrated signiﬁ  cant reduction in both disease recurrence (41%) and breast 
cancer speciﬁ  c mortality (34%) for patients treated with 5 years of tamoxifen therapy. 
Although most of the divergence between treatments in disease recurrence occurs 
during the ﬁ  rst 5 years on treatment, the effect on breast cancer speciﬁ  c mortality is not 
manifest until the period between 5 and 15 years. The relapse pattern for low-risk and 
intermediate risk tumors indicates that there is a 1.5% to 2% yearly risk of recurrence 
of breast cancer in years 5 to 15 after initial diagnosis. A small proportion of women 
treated with tamoxifen experience serious side effects including increased incidence 
of endometrial cancer, thromboembolism and cerebrovascular events, which limits 
the long-term use of tamoxifen. Recent data from the ATAC (Arimidex, Tamoxifen, Therapeutics and Clinical Risk Management 2009:5 292
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Alone or in Combination)5 and BIG (Breast International 
Group)1–986 clinical trials demonstrate that third-generation 
non-steroidal aromatase inhibitors (AIs) anastrozole and 
letrozole are, respectively, more effective than tamoxifen in 
reducing recurrences and also offer tolerability advantages 
over tamoxifen. A technology assessment from the American 
Society of Clinical Oncology (ASCO)7 recommends that the 
optimum adjuvant treatment for postmenopausal women with 
hormone-receptor-positive breast cancer should include the 
use of an AI, either as initial treatment or sequentially after 
2 to 5 years treatment with tamoxifen. Considerable debate 
remains over the most effective treatment strategy (upfront or 
sequential) and the extent to which beneﬁ  ts and side effects 
continue after treatment is completed.
In this report we review the 100-month analysis of 
the ATAC trial,8 which provides long-term efﬁ  cacy and 
safety data on anastrozole compared with tamoxifen as 
initial adjuvant treatment for postmenopausal women with 
hormone-sensitive breast cancer. Similarly the combined 
analyses of data from two prospective, multicenter, ran-
domized, open label trials (ABCSG trial 8 and ARNO 95) 
lend support to a switch from tamoxifen to anastrozole in 
patients who have completed 2 years of adjuvant tamoxifen.9 
The results of the Italian Tamoxifen Anastrozole Trial (ITA 
trial)10 also conﬁ  rm that switching to anastrozole after the ﬁ  rst 
2 to 3 years of treatment with tamoxifen is well tolerated and 
signiﬁ  cantly improves event-free and recurrence-free sur-
vival in postmenopausal patients with early breast cancer.
Pharmacology
The basic pharmacological differences between tamoxifen 
and anastrozole explain their mode of action, varied side 
effect proﬁ  le and efﬁ  cacy.
Tamoxifen is a selective estrogen receptor modulator 
(SERM), which affects different organ systems including 
the endometrium (endometrial cancer and hypertrophy), 
the coagulation system (thrombosis), bone (modulation 
of mineral density) and liver (alterations of blood lipid 
proﬁ  le). In these organ systems tamoxifen generally acts as 
an agonist, mimicking the effect of estrogen, in contrast to 
its action on breast epithelial cells, where it generally acts 
as an antagonist.11 Flare reactions, withdrawal responses, 
and the experimental demonstration of breast tumor growth 
stimulated by tamoxifen are evidence that tamoxifen 
can operate as an agonist in breast tissue under certain 
circumstances. Tamoxifen treatment is usually limited to 
5 years because of concerns on the development of de novo 
and acquired resistance, and an ongoing risk of adverse 
events, including endometrial cancer, thromboembolic 
events, and gynecological symptoms with long-term use.
The therapeutic option of reducing estrogen levels in 
patients with breast cancer was originally restricted to 
patients with functioning ovaries. However, postmenopausal 
women still produce signiﬁ  cant amounts of estrogen through 
aromatization of circulating adrenal androgens in peripheral 
normal tissues, such as fat, muscle, liver, and the epithelial and 
stromal components of the breast.11 The relative proportion 
of estrogens synthesized in extragonadal sites increases with 
age, and eventually non-ovarian estrogens predominate in the 
circulation. The pivotal role of aromatase in the development 
of breast cancer led to the successful introduction into 
clinical practice of potent and speciﬁ  c AIs. Anastrozole is a 
competitive AI with high potency and was the ﬁ  rst selective 
AI approved in North America and Europe. Pharmacodynamic 
studies reveal that subjects receiving anastrozole 1 mg per day 
orally achieved 96.7% aromatase inhibition.11
Efﬁ  cacy
The ATAC Trialists Group8 published in 2008 the ﬁ  ndings 
of an analysis of data at a median follow-up of 100 months 
(range 0–126), which is the longest follow-up to date of 
an adjuvant trial of upfront treatment with AIs. In ATAC, 
9366 postmenopausal women with localized invasive breast 
cancer treated with surgery ± radiotherapy ± chemotherapy 
were randomized on a 1:1:1 basis to anastrozole (n = 3125), 
tamoxifen (n = 3116) or a combination of anastrozole and 
tamoxifen (n = 3125). The combination treatment arm was 
discontinued after interim analysis because it showed no efﬁ  -
cacy or tolerability beneﬁ  ts over tamoxifen alone. The primary 
end point of the trial was disease-free survival (DFS) deﬁ  ned 
as the time from randomization to the earliest occurrence of 
local or distant recurrence, new primary breast cancer, or 
death from any cause, and the secondary endpoints included 
time to recurrence (TTR), incidence of new contralateral 
breast cancer (CLBC), time to distant recurrence (TTDR), 
overall survival (OS) and death after recurrence. The primary 
and secondary end points were assessed in the total population 
(intention to treat; ITT: anastrozole, n = 3125; tamoxifen, 
n = 3116: total 6241) and the hormone receptor positive 
subpopulation (84% of ITT: anastrozole, n = 2618; tamoxifen, 
n = 2598; total 5216). Post-treatment completion, fractures 
and serious adverse events continued to be collected blindly. 
A total of 46202 women-years of follow-up for patients 
receiving monotherapy were included in this trial.
The results of this trial show that at median follow-up of 
100 months, DFS, TTR, TTDR, and the incidence of new Therapeutics and Clinical Risk Management 2009:5 293
Anastrozole for early breast cancer
CLBC were improved signiﬁ  cantly in the intention to treat and 
hormone-receptor-positive populations in women assigned 
anastrozole compared to tamoxifen (Table 1). Lower recur-
rence rates for anastrozole were maintained after treatment 
completion, especially for the hormone-receptor-positive 
population where the absolute beneﬁ  t of 2.8% at 5 years 
increased to 4.8% at 9 years (Figure 1).
The improvement in disease control with anastrozole 
was maintained beyond 8 years and the graphs continued 
to diverge even at 9 years, suggesting that the therapeutic 
effect of 5 years’ treatment with AIs can be prolonged 
after treatment cessation. The Early Breast Cancer Trialists 
Collaborative Group (EBCTCG) showed a carryover effect 
for 5 years’ treatment with tamoxifen, with decreased 
recurrence rates maintained after cessation of treatment in 
years 5 to 9.4 Therefore, given the long-term ﬁ  ndings from 
the ATAC trial, anastrozole might have a larger carryover 
effect after cessation of treatment than tamoxifen, which may 
have a signiﬁ  cant impact on clinical practice. The additional 
signiﬁ  cant reduction in recurrence noted with anastrozole 
compared with tamoxifen after completion of treatment 
suggests that anastrozole would decrease recurrence by 50% 
in the post-treatment period compared with no treatment. 
The hazard ratio for recurrence favored anastrozole for all 
subgroups based on baseline and treatment characteristics. 
The benefit in favor of anastrozole was larger for the 
subgroup of estrogen-receptor-positive and progesterone-
receptor-negative compared to estrogen-receptor-positive 
and progesterone-receptor-positive subgroup (p = 0.001). 
However, this ﬁ  nding according to progesterone receptor 
status has not been confirmed either in a similar trial 
comparing letrozole with tamoxifen12 or by the Trans-ATAC 
Favours
anastrozole
Favours
tamoxifen
Events, n
AT
Hazard ratio
(95% Cl)
P
Disease-free survival
Time to recurrence
Time to distant
recurrence
Contralateral
breast cancer
Death-all causes
Death after
Death without
recurrence
recurrence
All patients (ITT)
Hormone-receptor-positive patients
0.4 0.6 0.8 1.0 2.0 1.2 1.5
817
618
391
305 357
702
494
887 0.90 (0.82−0.99) 0.025
0.003
0.0001
0.0004
0.022
0.020
0.85 (0.76−0.94)
0.76 (0.67−0.87)
0.84 (0.72−0.97)
0.81 (0.73−0.91)
0.86 (0.75−0.98)
0.68 (0.49−0.94)
0.60 (0.42−0.85)
538
424
629 624
645
487
0.022
61 87
50 80 0.004
1.00 (0.89−1.12) 0.99
472 477 0.97 (0.86−1.11) 0.7
350
279
227 208
242
382 0.91 (0.79−1.05)
1.12 (0.94−1.33)
0.2
0.2
0.2
0.6
245 269 0.90 (0.75−1.07)
1.05 (0.87−1.26)
Hazard ratio and 95% Cl
Table 1 ATAC trial: Efﬁ  cacy endpoints for all patients and hormone-receptor-positive patients
Reproduced with permission from The Arimidex, Tamoxifen Alone or in Combination (ATAC) Trialist’s Group (ATAC). Effect of anastrozole and tamoxifen as adjuvant treatment 
for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9:45–53.8 Copyright © 2008 Elsevier.
Abbreviations: A, anastrozole; T, tamoxifen; ITT, intention-to-treat.Therapeutics and Clinical Risk Management 2009:5 294
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investigators who investigated a subset of patients from 
whom tissue was able to assess a link between quantitative 
ER and PgR expression and HER2 status with recurrence 
in the ATAC.13
The distant recurrence rates also continued to diverge 
over longer follow-up intervals, being 1.3% lower for anas-
trozole compared with tamoxifen at year 5 and 2.4% lower 
at year 9. Similarly a lower number of recurrences of new 
contra-lateral breast cancers after anastrozole compared with 
tamoxifen were also maintained in the latest ﬁ  ndings from 
the ATAC trial.
However, despite the above ﬁ  ndings, no differences were 
noted in overall survival. The reasons for this are not entirely 
clear but may partly be because of an excess of deaths from 
other causes without recurrence (although not statistically 
signiﬁ  cant, about 44% of total deaths in the anastrozole group 
and 39% in the tamoxifen group were non-breast cancer 
deaths). The other important factor to be noted is that the 
mean age at last follow-up was 72 years in this analysis. The 
risk of major co-morbidities can increase with age, therefore 
deaths from causes other than breast cancer can be a major 
component of overall survival. In this trial no speciﬁ  c cause 
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Figure 1 ATAC trial: Curves for time to recurrence (TTR) in hormone-receptor-positive patients.  A) Kaplan-Meier prevalence curves and B) smoothed hazard rate curves 
for time to recurrence. Plots are smoothed with an Epanechinikov kernel with bandwidth chosen by cross validation.
Reproduced with permission from The Arimidex, Tamoxifen Alone or in Combination (ATAC) Trialist’s Group (ATAC). Effect of anastrozole and tamoxifen as adjuvant treatment 
for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9:45–53.8 Copyright © 2008 Elsevier. Therapeutics and Clinical Risk Management 2009:5 295
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of death was increased signiﬁ  cantly in patients assigned to 
anastrozole. Further analyses of ATAC, which are currently 
planned for 2010 when all patients will be more than 10 years 
post randomization, are eagerly awaited.
The sequential trials in which patients switched to 
anastrozole after 2 to 3 years on tamoxifen also show 
superiority of anastrozole over tamoxifen with better 
tolerability and safety proﬁ  le. A recent meta-analysis14 has 
included data from three clinical trials (ABCSG 8, ARNO, 
and ITA) in which postmenopausal women with histologically 
conﬁ  rmed, hormone-sensitive early-stage breast cancer were 
randomized to either 1 mg/day anastrozole (n = 2009) after 
2 to 3 years of tamoxifen treatment or continued on 20 or 
30 mg/day tamoxifen (n = 1997). Median follow-up for the 
meta-analysis was 30 months (0–89.5), with a total duration of 
follow-up of 5389 person-years for the anastrozole group and 
5339 person-years for the tamoxifen group. Patients switched 
to anastrozole had fewer disease recurrences (92 vs 159) and 
deaths (66 vs 90) than did those who remained on tamoxifen, 
resulting in signiﬁ  cant improvements in disease-free survival 
(hazard ratio 0.59 [95% CI 0.48–0.74]; p  0.0001), event-free 
survival (0.55 [0.42–0.71]; p  0.0001), distant recurrence-
free survival (0⋅61 [0⋅45–0⋅83]; p = 0.002), and overall survival 
(0.71 [0.52–0.98]; p = 0.04). The meta-analysis only included 
data for the time of switched treatment: its results therefore 
may not be relevant to a prospective treatment strategy of 
starting with tamoxifen with the intention of changing to 
anastrozole.
The efficacy and tolerability of extended adjuvant 
therapy with anastrozole for 3 years among women who 
had completed 5 years of adjuvant therapy were evaluated 
in the Austrian Breast and Colorectal Cancer Study Group 
(ABCSG) Trial 6a.15 In ABCSG Trial 6a, patients who were 
disease free at the end of ABCSG Trial 6 were randomly 
assigned to receive either 3 years of anastrozole or no further 
treatment. At a median follow-up of 62.3 months, women who 
received anastrozole (n = 387) had a statistically signiﬁ  cant 
reduced risk of recurrence (loco-regional recurrence, contra-
lateral breast cancer, or distant metastasis) compared with 
women who received no further treatment (n = 469; hazard 
ratio = 0.62; 95% CI = 0.40 to 0.96, p = 0.031).
Toxicity
Trial safety data show that the overall tolerability of AIs 
is similar to that of tamoxifen, with adverse events being 
predictably characteristic of estrogen deprivation; how-
ever, some important differences in adverse event proﬁ  les 
between tamoxifen and the AIs have been demonstrated. 
In addition to anti-estrogenic effects, tamoxifen acts as an 
estrogen agonist in some tissues, which can lead to serious 
side effects not associated with the AIs, which prevent 
estrogen biosynthesis. A lower incidence of gynecological 
and thromboembolic events is observed in patients taking AIs, 
and fewer cases of endometrial cancer are seen compared with 
tamoxifen. Adverse events that are more frequent with adjuvant 
AI therapy compared with tamoxifen include arthralgia and 
myalgia, bone loss, and effects on the cardiovascular system 
and blood lipids. The effects of AIs on bone are predictable and 
may be managed, where necessary, with bisphosphonates.
Overall, treatment-related serious adverse events were 
fewer in patients receiving anastrozole in the ATAC trial 
compared with those receiving tamoxifen during the 
treatment period and similar after treatment completion. The 
safety proﬁ  les for anastrozole and tamoxifen in the sequential 
studies were consistent with those previously reported in 
other trials,9,10,16 and no new safety issues were identiﬁ  ed 
within the context of switching therapy after 2 to 3 years.
Cardiovascular and thromboembolic events
Although an increase in cardiovascular risk associated with 
estrogen depletion is a potential concern with AIs,17 there 
was no difference in the number of cardiovascular deaths 
between the anastrozole and tamoxifen groups (67 [2%] 
vs 66 [2%]) in the 100-month analysis of the ATAC trial; 
moreover, the incidence of myocardial infarction was similar 
between the two groups, both during treatment (34 [0.27%] 
vs 33 [0.27%]) and off treatment (26 [0.28%] vs 28 [0.30%]). 
Fewer cerebrovascular accidents were noted in patients 
receiving anastrozole during treatment (20 vs 34, odds 
ratio [OR] 0.59 [0.32–1.05], p = 0.056), but not afterwards 
(22 vs 20, OR 1.10 [0.57–2.13], p = 0.75). The incidence of 
thromboembolic events was also decreased with anastrozole 
during treatment.
Gynecological and menopausal symptoms
In the ATAC trial, patients randomized to tamoxifen had sig-
niﬁ  cantly more gynecologic adverse events than those in the 
anastrozole group (34.2% vs 20.5%; p  0.0001), which led 
to more diagnostic and/or therapeutic interventions, includ-
ing an increase in the number of hysterectomies (5.1% vs 
1.3%; p  0.0001).18 Decreased libido and dyspareunia 
were reported more frequently with anastrozole than with 
tamoxifen, and most of these events were in patients who 
had vaginal dryness. Recently Cuzick and others19 reported 
a retrospective analysis of the ATAC trial to investigate 
the association between treatment-emergent endocrine Therapeutics and Clinical Risk Management 2009:5 296
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symptoms (speciﬁ  cally vasomotor and joint symptoms) and 
the risk of breast cancer recurrence. Vasomotor symptoms 
(eg, hot ﬂ  ushes, night sweats, and cold sweats) are common 
side effects of endocrine treatment in women with breast 
cancer: in the ATAC trial, around 35% of patients receiving 
anastrozole and 40% of those receiving tamoxifen reported 
hot ﬂ  ushes during treatment. Excluding patients who already 
had vasomotor symptoms and/or joint symptoms at baseline, 
the study by Cuzick shows that 21.7% and 25.8% of patients 
randomized to anastrozole or tamoxifen, respectively, reported 
vasomotor symptoms at the 3-month follow-up visit, and 
21.1% and 14.3% reported joint symptoms. The emergence 
of either symptom was predictive of signiﬁ  cantly lower recur-
rence risk in both tamoxifen-treated and anastrozole-treated 
patients, even after adjustment for age, BMI, previous HRT, 
nodal status, tumor size, and tumor grade. A signiﬁ  cantly 
larger effect was noted for joint symptoms (adjusted HR 0.60 
[0.50–0.72], p  0.0001), which was similar in both treat-
ment groups, whereas the effect of vasomotor symptoms was 
smaller and most apparent in patients who had taken HRT 
before study entry. A similar correlation of side-effects with 
response to treatment has been noted in a few other situations, 
notably graft-versus-host disease for allogeneic bone-marrow 
transplantation and skin rash for antibodies directed at the 
EGFR or tyrosine-kinase inhibitors. An inverse association 
between the occurrence of vasomotor symptoms and breast 
cancer recurrence was previously reported for tamoxifen,20 
and extends this association to the AI anastrozole and also to 
the presence of joint symptoms. If conﬁ  rmed, this relationship 
between early treatment-emergent symptoms and beneﬁ  cial 
response to therapy might be useful when reassuring patients 
who present with these symptoms, and also suggests the 
need for effective strategies to manage patients in order to 
ensure compliance.
Quality of life
A subgroup of patients in the ATAC trial were assessed 
for quality of life21 using the FACT-B questionnaire and 
endocrine symptoms (ES) subscale assessment of ES 
at baseline and 3, 6, 12, 18 and 24 months During the 
2-year assessment period most patients showed a clinically 
signiﬁ  cant improvement from baseline in the aggregate of 
their physical well-being, functional well-being and breast 
cancer speciﬁ  c concerns, as measured by the FACT-B Trial 
Outcome Index. Conversely, most patients in each treatment 
arm experienced a worsening of endocrine-related symptoms 
at the 3 month assessment relative to baseline. Thereafter 
these symptoms appeared to stabilize or improve slightly. 
There were some interesting differences in the reporting 
of the severity of individual endocrine symptoms among 
treatment groups. Women taking anastrozole reported fewer 
cold sweats, but the same number of hot ﬂ  ushes. Although 
vaginal discharge was reported less often by women taking 
anastrozole than women taking tamoxifen, significant 
vaginal dryness was more common on anastrozole, as was 
dyspareunia and loss of interest in sex.
Other primary cancers
Deaths due to second primary non-breast cancers and 
deaths due to other causes were numerically more frequent 
in patients assigned anastrozole in the 100-month analysis 
of the ATAC trial, although differences with tamoxifen are 
statistically not signiﬁ  cant. Endometrial cancers, melanomas 
and ovarian cancers were less frequent with anastrozole, but 
there were more lung and colorectal cancers: only in the case 
of endometrial cancer, however, was the difference with 
tamoxifen statistically signiﬁ  cant.
A link between estrogens and a decreased risk of 
developing colorectal cancer has been postulated22. In 
addition, estrogen receptors α and β have been shown to 
inhibit the development of adenomatous polyposis coli (APC)-
dependent colon cancer in mice.23 By contrast, aromatase 
seems to enhance disease progression in lung cancers,24 
suggesting that the role of estradiol in tumor progression or 
tumor regression could be diverse and dependent on cancer 
type. Since estrogen receptor β is widely expressed in many 
organs, the effects of hormone manipulation on non-breast 
malignant disease occurrence needs to be assessed further. 
This highlights the need to continue collecting follow-up data 
in the adjuvant AI trials.
Fractures
The 68-month analysis of ATAC trial25 revealed that 
treatment-related adverse events occurred signiﬁ  cantly less 
often with anastrozole than with tamoxifen (1884 [61%] 
vs 2117 [68%]; p  0.0001), as did treatment-related 
serious adverse events (146 [5%] vs 277 [9%]; p  0.0001) 
and adverse events leading to withdrawal (344 [11%] vs 
442 [14%]; p = 0.0002). However, it was also noted that 
the fractures occurred more often in patients receiving 
anastrozole compared to the patients receiving tamoxifen 
(340 [11%] vs 237 [8%]; p  0.0001). The yearly rate of 
fracture remained constant over the treatment period and 
was higher for anastrozole than for tamoxifen (22.6 vs 
15.6 fractures per 1000 women-years; HR 1.43 [95% CI 
1.21–1.68]; p  0.0001). Excess fractures were recorded at Therapeutics and Clinical Risk Management 2009:5 297
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several sites including the wrist, humerus or arm, and spine 
but hip fracture occurrence was low in both groups (37 [1%] 
vs 31 [1%]). The concomitant use of bisphosphonates was 
recorded at every follow-up visit, and overall use was low 
in both groups. In the 100-month ATAC analysis,8 the 
increased yearly rate of fracture noted in the anastrozole 
group compared with tamoxifen did not continue into the 
post-treatment period, where the rate on anastrozole was 
similar to that on tamoxifen. Therefore the increase in fracture 
rates with anastrozole persisted only in the active treatment 
period and did not continue after treatment completion. It is 
interesting to note that although the effects of anastrozole and 
tamoxifen on breast cancer recurrence extended beyond the 
cessation of treatment, the higher fracture rates on anastrozole 
ceased after the 5-year treatment completion (Figure 2). It 
has been noted that hip fractures were little affected by anas-
trozole in this study and although there is 6% to 7% bone 
loss during active treatment, no patients with normal bone 
density at baseline developed osteoporosis after 5 years’ 
treatment.26,27 This suggests that bone damage by aromatase 
inhibition may be reversible and manageable with the use of 
bisphosphonates, although the mechanisms of action of the 
bone damage by AIs and subsequent recovery after treatment 
completion are still unclear.
Bisphosphonate therapy reduces bone destruction 
and the incidence of subsequent skeletal complications 
in the metastatic disease setting, and recent results have 
demonstrated their efﬁ  cacy in the prevention of AI-associated 
bone loss (AIBL) in patients with early breast cancer.28–30
In one large trial, premenopausal women who received 
tamoxifen or anastrozole, both in combination with goserelin 
(n = 401), were randomized to receive zoledronic acid or no 
additional treatment.19 Zoledronic acid (4-mg infusion every 
6 months) added to both therapy combinations effectively 
preserved bone mineral density (BMD) and concomitant 
zoledronic acid not only prevented bone loss during therapy 
but improved BMD at 5 years. Data on fracture rates 
with these two treatment strategies are not yet reported. 
The efﬁ  cacy of zoledronic acid for prevention of AIBL 
in postmenopausal women was evaluated by three large 
parallel designed trials20,21 (Z-FAST, ZO-FAST, and E-ZO-
FAST) which randomized patients – who received letrozole 
2.5 mg/day for up to 5 years – to zoledronic acid 4 mg every 
6 months either at initiation of letrozole treatment (immediate 
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Figure 2 Fracture episodea rates throughout the ATAC Trialists’ Group study.
aA fracture episode comprised one or more fractures on the same day. Fractures occurring after recurrence are not included because patients were censored after recurrence 
and fractures were not recorded.
Reproduced with permission from The Arimidex, Tamoxifen Alone or in Combination (ATAC) Trialist’s Group (ATAC). Effect of anastrozole and tamoxifen as adjuvant treatment 
for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9:45–53.8 Copyright © 2008 Elsevier. Therapeutics and Clinical Risk Management 2009:5 298
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group) or at the time of BMD decline (T-score  2 standard 
deviations below normal or an occurrence of fracture; 
delayed group).31–33. The enrolment included 602 women in 
the Z-FAST study (United States and Canada), 1066 women 
in the ZO-FAST study (approximately 30 countries outside 
the United States), and 527 women in the E-ZO-FAST study 
(66 countries in South America, the Middle East, Korea, 
Europe, and South Africa).34,35. The primary endpoint was 
the change from baseline in lumbar spine BMD after 1 year 
of treatment.
At 1 year in the Z-FAST study immediate zoledronic 
acid (n = 301) provided signiﬁ  cant mean increases in lumbar 
spine and total hip BMD (p  0.0001 for both) compared 
with delayed treatment (n = 301).23 Among patients in the 
delayed group, 8.3% met the requirement for zoledronic 
acid treatment at 12 months. At both 24 and 36 months, 
lumbar spine and total hip BMD continued to increase in the 
immediate zoledronic acid group, whereas BMD continued 
to decrease further in the delayed-treatment group.22 In the 
ZO-FAST, study lumbar spine BMD increased from base-
line in the immediate group and decreased from baseline in 
the delayed group. At month 12, the differences between the 
treatment groups in lumbar spine and total hip BMD were 
5.7% (95% CI: 5.2%–6.1%; p = 0.0001) and 3.6% (95% CI: 
3.3%–4.0%; p = 0.0001), respectively.38 At month 24, the 
differences between the treatment groups in lumbar spine 
and total hip BMD increased to 8.2% and 4.7%, respectively 
(p  0.0001 for both). In both studies, levels of biochemical 
markers of bone metabolism increased in the delayed group, 
but were reduced with zoledronic acid therapy. Currently, 
follow-up is too short for assessing fracture incidence. At 
1 year in the E-ZO-FAST studies the differences between the 
treatment groups in lumbar spine and total hip BMD were 
5.4% and 3.3%, respectively (p  0.0001 for both).
Recently, guidance on management of cancer treatment-
induced bone loss has emerged and the American Society 
of Clinical Oncology published an update on the role of 
bisphosphonates and bone health issues in women with 
Breast Cancer.36 Recommendations were given for regular 
assessments of bone health to screen for osteoporosis. 
Treatment for bone loss was recommended in breast cancer 
patients found to have osteoporosis based on BMD results 
(t score –2.5 or lower). Breast cancer patients found to 
have osteopenia based on BMD results (t score between –1 
and –2.5) should have their therapy individualized according 
to other risk factors. Other recent guidelines have suggested 
a slightly more cautious level for intervention (t score  2.0) 
and the use of bone-targeted treatment in patients with multiple 
risk factors for fracture regardless of BMD and/or bone loss of 
more than 4% per year at either the hip or lumbar spine.37
Arthralgias
Arthralgia is an adverse class effect of AIs. Morales et al 
recently reported a prospective study to investigate the 
changes in clinical rheumatologic features and magnetic 
resonance imaging (MRI) of hands and wrists in AI and 
tamoxifen users.38 At 6 months, patients on AI had a decrease 
in grip strength (p = 0.0049) and an increase in tenosynovial 
changes (p = 0.0010) on MRI compared to only minor 
changes seen in patients on tamoxifen. AI users reported 
worsening of morning stiffness and showed an increase in 
intra-articular ﬂ  uid on MRI.
Crew and others39 conducted a cross-sectional survey 
of consecutive postmenopausal women receiving adjuvant 
AI therapy for early-stage hormone-sensitive breast cancer 
at an urban academic breast oncology clinic. Among the 
200 patients who completed the questionnaire assessing 
the presence of joint symptoms that started or worsened 
after initiating AIs, 94 (47%) reported having AI-related 
joint pain and 88 (44%) reported AI-related joint stiffness. 
In multiple logistic regression analysis, being overweight 
(BMI 25 to 30 kg/m2) and prior tamoxifen therapy were 
inversely associated with AI-related joint symptoms. 
Patients who received taxane chemotherapy were more than 
4 times more likely than other patients to have AI-related 
joint pain and stiffness (OR = 4.08, 95% CI, 1.58–10.57 
and OR = 4.76; 95% CI, 1.84–12.28, respectively). This 
study suggests that AI-related joint symptoms are more 
prevalent in the real world setting than what has been 
described in clinical trials, where arthralgias are reported 
in 20% to 35% of the patients treated with an AI. The 
success of AI therapy may depend on patients’ ability to 
be compliant with treatment recommendations; therefore, 
additional studies of interventions that may alleviate these 
symptoms are needed.
Conclusions
Long-term follow up data from the ATAC trial conﬁ  rm the 
efﬁ  cacy of anastrozole as adjuvant treatment for postmeno-
pausal women with hormone-sensitive early breast cancer, 
and provide evidence of a carryover effect after completion 
of 5 years of treatment. The safety proﬁ  le of anastrozole is 
also conﬁ  rmed to be favorable, with a predictable pattern 
of estrogen-deprivation symptoms (vasomotor symptoms, 
joint symptoms and bone loss) which clinicians need to 
recognize and manage according to local guidelines. Some of Therapeutics and Clinical Risk Management 2009:5 299
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the side effects, especially joint symptoms, may also predict 
a decreased risk of recurrence: this could help in reassuring 
women and improving compliance.
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